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ABSTRACT
Esophagogastric cancers are serious malignancies with high mortality and low overall 
survival for advanced tumors. Detection of premalignant lesions and early treatment 
of malignant lesions are of paramount importance. Precancerous esophagogastric 
conditions develop from interaction between environmental and genetic factors. Chronic 
irritation and inflammation may result in metaplasia, increased mutations, cellular 
atypia, and altered function (dysplasia). Helicobacter pylori (HP) infection is one of 
the most important risk factors for gastric carcinogenesis, but other environmental 
factors (e.g. alcohol, tobacco, nitrites, infection) and autoimmune disorders play a role 
as well. Esophageal adenocarcinoma (EAC) usually arises in the distal esophagus and 
is linked to obesity, gastroesophageal reflux disease (GERD) and Barrett’s esophagus 
(BE). Squamous cell carcinoma (ESCC) typically occurs in the presence of risk factors 
causing chronic inflammation (e.g. tobacco, alcohol abuse, achalasia, tylosis). High-
quality endoscopic imaging is of primary importance in the diagnosis and assessment 
of premalignant and early malignant esophagogastric lesions. Biological markers such 
as aberrant p53 protein expression may be associated with increased risk of malignant 
transformation of precancerous lesions; however, none of those biomarkers has been 
validated for either diagnosis or risk stratification yet.
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Background:
Esophagogastric cancers are serious malignancies 
with high mortality and an overall 5-year survival of 
less than 20% for advanced tumors [1-3]. To reduce 
this burden, prevention as well as early detection and 
treatment of premalignant or early malignant lesions are 
of paramount importance.
Precancerous esophagogastric conditions generally 
develop from a complex interaction between 
environmental and genetic factors against a background 
of chronic inflammation [4]. Basically, chronic irritation 
can result in metaplasia, the process in which one type 
of tissue is replaced by another that is presumably better 
able to resist injury from the underlying condition. 
However, persistent inflammatory cells can trigger 
a multistep, sequential process of carcinogenesis 
by producing cytokines and oxidant products that 
damage cellular DNA, RNA, and proteins, resulting in 
increased mutations, cellular atypia and altered function 
(dysplasia). Due to increased genetic alterations, this 
disordered proliferation of cells extends into deeper 
layers and determines invasive carcinoma [4-6].
This article reviews the current status of diagnosis and 
management of premalignant and early malignant 
conditions of the esophagus and stomach. The role of 
the most significant risk factors is also discussed, and 
technological advances in early cancer detection are 
reported.
Premalignant conditions and esophageal cancer
There are two predominant types of primary esophageal 
cancers, namely squamous cell carcinoma (ESCC) and 
adenocarcinoma (EAC), which differ with regards to 
etiology, ethnic distribution, pathogenesis, location in the 
esophagus, and precursor lesions [1,3]. Although ESCC 
is the most common esophageal cancer worldwide, EAC 
is the most frequent form in Western countries, where it 
has been recorded an estimated 350% increase over the 
last half century, probably linked to increase in obesity 
and gastroesophageal reflux disease (GERD) [3,6].
As far as ESCC is concerned, this type of cancer arises 
from the squamous epithelial lining of the esophagus 
(usually in the middle third, less commonly in the 
lower third or upper esophagus) through progression 
of a disordered proliferation of cells occurring in the 
presence of risk factors causing chronic inflammation 
(e.g. tobacco, alcohol abuse, achalasia, tylosis) [3-4,6]. 
According to the extent of epithelial involvement by 
atypical cells, squamous dysplasia can be distinguished 
in low-grade dysplasia, when less than half of thickness 
of epithelium is involved, and high-grade dysplasia, 
when greater than half of thickness is involved. Full-
thickness involvement is termed non-invasive squamous 
cell carcinoma, whereas invasion into lamina propria 
and deeper layers defines invasive ESCC, with variable 
histological differentiation [4,6]. However, changes in the 
mucosa are usually subtle in the early stages of cancer, 
passing unnoticed at normal endoscopic examination, 
thus ESCC tends to present late with dysphagia, weight 
loss and retrosternal pain [4-7]. 
As previously stated, ESCC rates in Western countries 
have declined over the last few decades, while EAC 
incidence has increased dramatically, becoming the 
most frequent esophageal cancer in the United States 
and Western Europe [1,3,6]. 
EAC is a carcinoma with glandular differentiation 
which usually arises in the distal esophagus, in the 
setting of Barrett’s esophagus (BE). As a matter of fact, 
BE is the only recognized precursor of EAC and its most 
important etiological factor. Other risk factors include 
GERD, obesity, male sex, Caucasian race, and tobacco 
smoking, whereas HP infection seems to be inversely 
correlated to EAC [3,6,8-9].
BE is defined as columnar metaplasia that replaces the 
stratified squamous epithelium of the distal esophagus, 
spanning in the form of tongue-shaped metaplastic 
islets from the gastroesophageal junction (GEJ) into the 
distal esophagus. The diagnosis of BE requires both 
endoscopic and pathologic evaluation [3,6]. According 
to the most recent recommendations by the American 
College of Gastroenterologists (ACG), BE should be 
diagnosed when there is extension of salmon-colored 
mucosa ≥ 1 cm proximal to the GEJ on endoscopy and 
presence of intestinal metaplasia (IM; i.e. intestinal-
type goblet cells) on biopsy evaluation [10]. However, 
there is international disagreement regarding whether 
a distal esophagus lined by cardiac mucosa, which also 
has intestinal features but lacks goblet cells, represents a 
metaplasia that qualifies for BE diagnosis [11]. Indeed, 
it is now widely accepted that any type of columnar 
mucosa located proximal to the GEJ is metaplastic in 
origin and has developed following chronic injury 
due to GERD. Thus, BE represents the end-result of 
this metaplastic transformation of normal squamous 
epithelium into columnar epithelium [12-14]. Once 
formed, the metaplastic epithelium can present a gastric 
differentiation, characterized by the formation of parietal 
cells within glands, or an intestinal differentiation, 
characterized by the formation of goblet cells within 
the columnar epithelium. The latter transformation is 
considered an unfavorable change because the mucosa 
is capable of further progression to epithelial dysplasia 
and adenocarcinoma. However, the molecular pathway 
by which the columnar epithelium differentiates in one 
way or the other remains elusive [8,10-14].
The presence of BE is associated with a 30- to 50-fold 
increased risk of developing EAC. However, the rate of 
progression from BE to EAC is only 0.1-0.3% per year 
and up to 80-90% of EAC patients report no previous 
history of BE [12]. Therefore, there is considerable 
interest in understanding the pathological mechanisms 
determining how BE develops and who will progress to 
EAC. As far as non-genetic factors are concerned, GERD 
is the strongest known factor for the development of 
BE and EAC [3,8]. Its prevalence is rising worldwide 
and medical therapy (e.g. proton pump inhibitors, H2-
receptor antagonists, alginate formulations) has shown 
excellent results in controlling GERD symptoms (e.g. 
heartburn, regurgitation, hoarseness, chronic cough, 
chest pain, dysphagia) [8]. However, no medication 
seems to prevent metaplastic progression and around 
10-15% of patients with GERD will eventually develop 
BE. This transformation may take several years to 
happen and is provoked by the chronic injury produced 
by recurrent reflux episodes. Therefore, the duration of 
reflux is the most important factor in determining BE 
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[3,8,10-12]. Recently, much work has focused also on the 
potential role of the upper gastrointestinal microbiome 
as a cofactor in BE and EAC. Although results are far 
from being conclusive, preliminary outcomes suggest 
that there is a significant alteration in the resident flora 
of pathological states and these changes may contribute 
to the pathogenesis of metaplasia and dysplasia [15].
In the context of BE, the presence and grading of 
dysplasia are the most important factors in predicting 
the development of EAC [3,8]. Indeed, annual incidence 
of EAC is 0.5% in patients with low-grade dysplasia 
compared to 7% in patients with high-grade dysplasia 
[8]. Therefore, considering that endoscopic therapy is 
highly effective for the eradication of BE and associated 
dysplasia, patients with high-grade dysplasia should be 
promptly referred for endoscopic management [3,10]. 
Other risk factors for dysplasia include increasing length 
of BE (with greater prevalence of dysplasia in BE length 
≥ 3 cm), advancing age, central obesity, male sex, and 
smoking [3,10].
High-quality endoscopic imaging is of primary 
importance also in the diagnosis and assessment of 
premalignant and early malignant esophageal lesions. 
Squamous dysplasia is usually asymptomatic, and 
the mucosa may either appear completely normal at 
standard white light endoscopy (WLE) or show mucosal 
changes, such as erythema, erosions, friability, plaques, 
and nodules [6]. In order to increase the sensitivity of 
lesion detection, the visualization of the surface mucosa 
and underlying capillary pattern can be enhanced either 
through conventional chromoscopy (i.e. with Lugol’s 
solution injection) or by using virtual methods like 
narrow band imaging with magnification endoscopy 
(NBI-ME), which enhance subtle mucosal changes 
without the risk inherent to the use of vital dye [7].
As far as molecular markers are concerned, several 
studies have attempted to assess the utility of biological 
markers to predict progression and assist with risk 
stratification. Specifically, aberrant p53 protein 
expression may be associated with increased risk of 
malignant transformation of BE [3,7]. However, to date 
none of the potential molecular biomarkers has been 
validated for either diagnosis or risk stratification [10-
12].
Premalignant conditions and gastric cancer
According to the persistent inflammatory irritation 
model, the pathogenesis of gastric cancer can be explained 
by a sequential progression from chronic gastritis 
through atrophic gastritis (AG), intestinal metaplasia 
(IM), and dysplasia to invasive adenocarcinoma (the 
“Correa” cascade) [5,16]. In this context, AG and IM 
are considered the main precursor lesions of gastric 
cancer as its incidence increases in the gastric mucosa 
involved with AG and IM [5,16-18]. Specifically, AG 
is characterized by the loss of gastric glandular cells, 
which can be caused by either intrinsic (e.g. autoimmune 
disorders) or environmental factors (e.g. alcohol, 
tobacco, nitrites, infection) [4]. The risk of gastric cancer 
increases with the extent and degree of mucosal atrophy 
and AG is considered to be an antecedent to IM [2,4-5]. 
Histologically, IM can be either complete or incomplete. 
Complete IM resembles small intestinal glands, with 
loss of gastric mucins and presence of eosinophilic 
enterocytes with an identifiable brush border, well-
defined goblet cells, and occasional Paneth cells at the 
base of the gland. Incomplete IM (also known as gastric 
IM) is characterized by a combination of gastric foveolar 
epithelium and intestinal goblet cells, with simultaneous 
expression of both gastric and intestinal mucins [18]. 
Although the prognostic implication of IM subtypes is 
currently uncertain, several studies have suggested that 
incomplete IM has a higher proliferative index resulting 
in a higher risk of progression to cancer [18-19].
Among the several factors that have been considered 
playing a role in gastric carcinogenesis, Helicobacter pylori 
(HP) infection is currently the most important risk factor 
for AG, IM, and gastric cancer [2,17,20]. Epidemiological 
studies suggest that HP strains containing the cagA gene 
are more virulent and its prevalence varies according to 
ethnicity and geographical location [2,19-22]. Therefore, 
eradication of HP infection is regarded as a primary 
chemoprevention strategy for reducing the incidence 
of gastric cancer. However, it has to be noted that only 
1-2% of HP-positive subjects will eventually develop 
gastric cancer and HP is generally absent from areas 
with IM, suggesting that other environmental and 
host factors are involved in the carcinogenesis [2,5,20-
22]. In this context, a Swedish study recently evaluated 
the role of non-HP microbiota in the development of 
gastric cancer through the multistep “Correa cascade” 
[23]. Ndagwe et al. analyzed 316 individuals from a 
low HP prevalence general population and appraised 
differences in stomach microbial composition across the 
healthy and disease states, with AG and non-atrophic 
HP gastritis presenting the lowest microbial diversity. 
In particular, the Swedish group found an increasing 
abundance of pathogenic bacteria from normal stomach 
to early precancerous states and postulated that some 
of the identified non-HP bacteria may potentially 
play a role in promoting inflammation and gastric 
carcinogenesis through N-nitroso compounds or urease 
production. However, the role of gastric microbiota 
and the molecular pathways are far from being fully 
disclosed. 
Another factor that has been extensively examined in 
several observational studies is obesity, although results 
are mostly inconclusive [21-22]. Recently, a large cohort 
analysis by Kim et al. [24] showed that obesity was 
associated with a higher incidence of AG and IM, with 
risk increasing as BMI category increased. In addition, 
the Korean study demonstrated that the positive 
association between BMI and IM was more evident in 
individuals younger than 40 years old, suggesting that 
accumulative exposure to other environmental factors 
may play a role in the prevalence of gastric cancer and 
its precancerous lesions with more advancing age.
The first step into diagnosis and assessment of gastric 
premalignant conditions is standard WLE associated by 
random mucosal biopsies to stage the extent and severity 
of gastritis and possible IM [5,19-20]. Macroscopically, 
the main endoscopic features of AG are loss of gastric 
rugae, mucosal pallor and increased visibility of mucosal 
vessels, whereas IM typically appears as an irregular 
surface characterized by small, grey-white, elevated 
plaques surrounded by mixed patchy pink and pale 
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areas of mucosa [19-20]. However, these macroscopic 
findings are neither sensitive nor specific and a higher 
degree of diagnostic accuracy can be achieved by using 
NBI-ME, which can reliably identify normal gastric 
mucosa, HP-associated gastritis, AG, and IM, thus 
supporting targeted biopsies that can lead to more 
accurate risk assessment [19-20]. Specifically, NBI-ME 
with or without chromoendoscopy (i.e. methylene blue, 
indigo carmine, and/or acetic acid) can increase the 
sensitivity up to 94% for detection of IM [19].
As for the role of serologic markers, several studies 
have demonstrated a possible significant association 
with digestive enzymes levels. Specifically, a decreased 
pepsinogen I/II ratio appears to be associated with higher 
risk of IM and gastric cancer, whereas increased serum 
gastrin levels are associated with AG [19]. However, 
current evidence is still ambiguous and further studies 
are required to provide definite conclusions.
Conclusion
Esophagogastric cancers are serious malignancies with 
high mortality. Prevention as well as early detection 
and treatment of premalignant or early malignant 
lesions are of paramount importance. Esophagogastric 
malignancies generally develop from precancerous 
conditions in a setting of a complex interaction between 
environmental and genetic factors. Inflammation can 
trigger a multistep, sequential process of carcinogenesis 
resulting in increased mutations, cellular atypia and 
dysplasia, which eventually may determine carcinoma. 
Since frequently asymptomatic, high-quality white 
light endoscopy imaging and biopsies are the first 
steps into diagnosis and assessment of gastric and 
esophageal premalignant conditions. Visualization can 
be enhanced either through conventional chromoscopy 
or by using virtual methods.  Some biological markers 
may be associated with increased risk of malignant 
transformation of precancerous lesions, but to date, 
the utility of those markers to make diagnosis, predict 
progression and assist with risk stratification, is still not 
validated.
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